TAO Synergies (TAOX) FY2025 10-K Risk Factors: 30 New, 5 Dropped

What the changes say

Company pivoted into a crypto strategy aiming to acquire $100 million of TAO tokens, relying heavily on consultant James Altucher.

What changed since the prior 10-K

New

New
There is no assurance that any crypto asset will maintain its value or that there will be meaningful levels of trading activities. In the event that the price of crypto assets or the demand for trading crypto assets decline, our business, operating results, and financial condition could be adversely affected
Crypto asset holdings may lack liquidity and stable trading values, harming working capital.
New
Certain of our directors, officers, employees and independent contractors may hold crypto assets
Directors, officers, and employees holding personal crypto assets could experience conflicts of interest.
New
We are highly dependent on James Altucher and other key personnel, and our inability to retain or attract experienced individuals could materially harm our business
The company relies heavily on TAO token consultant James Altucher, whose contract expires on June 8, 2026.
New
Our TAO holdings are likely to be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents
TAO holdings suffer from significant price volatility, low trading volumes, and restricted platform availability.
New
Regulatory change classifying certain digital cryptocurrency assets as “securities” could lead to our being subject to extensive regulation, which could result in significant costs or force us to cease operations
Future regulatory classification of digital assets as securities could subject the company to the Investment Company Act of 1940.
New
We will likely need to pursue additional equity or debt financings to meet our previously announced goal of acquiring $100 million of TAO
The company needs additional debt or equity financing to reach its $100 million TAO acquisition goal.
New
Our historical financial statements do not reflect the potential variability in earnings that we may experience in the future relating to our proposed holdings of crypto assets
Quarterly impairment analyses for crypto holdings will introduce substantial earnings volatility.
New
The emergence or growth of other crypto assets, including those with significant private or public sector backing, could have a negative impact on the price of TAO and adversely affect our business
Assets are concentrated solely in TAO, exposing the company to competition from alternative AI crypto assets.
NewRisks Related to the Custodian and Prime Broker
We face additional risks related to our reliance on BitGo Prime LLC (the “Prime Broker”) and BitGo Trust Company, Inc. (the “Custodian”), which are affiliated entities, for trading, custody, and settlement of TAO
Operations rely on BitGo Prime LLC and BitGo Trust Company for TAO trading, custody, and settlement.
NewRisks Related to the Custodian and Prime Broker
Security threats to the Company’s account at the Custodian could result in the halting of the Company’s operations and a loss of the Company’s assets or damage to the reputation of the Company, each of which could materially and adversely affect the Company
Custodial accounts held at BitGo are vulnerable to security breaches, hacking, and theft of TAO assets.
NewRisks Related to Staking
Staking activities involve significant risks, including the risks of borrower default, operational failures and the potential loss of TAO, which could materially and adversely affect our financial performance and the value of our crypto assets
Staking TAO restricts liquidity and concentrates 90% of root subnet staking with Yuma until November 5, 2027.
NewRisks Related to Staking
Moreover, if any on-chain or implied protocol terms conflict with the Yuma Agreement, the agreement prevails. As the Bittensor protocol evolves, this “paramountcy” may cause frictions with network norms or expectations and may limit our ability to rely on protocol-level terms if they diverge from our contract
Protocol terms conflicting with the Yuma Agreement could create legal and operational friction.
NewRisks Related to Staking
Our reliance on the Custodian and its third-party validator for TAO staking activities creates concentration and related risks
NewRisks Related to Staking
Our TAO staking relies on the Custodian and our Validators, who may utilize subnet automated market maker (“AMM”) pools, exposing us to additional liquidity, market, and operational risks beyond our direct control
NewRisks Related to Staking
If crypto assets held by us are determined to be securities under U.S. federal or state law, we would become subject to significant regulatory burdens, which may materially and adversely affect its business, operations, and financial condition
NewRisks Related to Our Media Platform
Our ownership and operation of The TAO Daily, an online news publication and data provider in the digital asset industry, presents a number of significant risks, including those arising from perceived or actual conflicts of interest
NewRisks Related to Our Media Platform
Our strategy and focus on delivering high-quality, regulated, easy-to-use, and secure digital asset-related information through our media platform The TAO Daily may not maximize short-term or medium-term financial results
NewRisks Related to Our Media Platform
Our success depends on our ability to effectively improve and scale our technical and data infrastructure
NewRisks Related to Our Media Platform
Security incidents and other network and information systems disruptions could affect our ability to conduct our business effectively, cause us to incur significant costs, subject us to significant liability and/or damage our reputation
NewRisks Related to Our Media Platform
Our business depends on continued and unimpeded access to the internet and cloud-based hosting services we utilize
NewRisks Related to Our Media Platform
Our advertising revenues are affected by numerous factors, including market dynamics, evolving digital advertising trends and the evolution of our strategy
NewRisks Related to Our Media Platform
The open-source structure of crypto asset networks, including the Bittensor network on which the TAO crypto asset functions, exposes us to risks related to software development, security vulnerabilities, and potential disruptions
NewRisks Related to Our Media Platform
The irreversibility of crypto asset transactions exposes us to risks of theft, loss and human error, which could negatively impact our business
NewRisks Related to Our Media Platform
Decentralized AI networks, such as Bittensor, involve special risks related to unclear regulatory requirements, technical difficulties, limited transparency, intense competition, and complex intellectual property considerations
NewRisks Related to Our Media Platform
We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds, or to obligations applicable to investment advisers or other regulated entities
NewRisks Related to Our Media Platform
Potential classification of our crypto asset activities including staking as money transmission could subject us to additional regulatory requirements, resulting in significant compliance costs or the cessation of certain operations
NewRisks Related to Our Media Platform
Regulatory scrutiny or shifting enforcement priorities could subject our crypto asset activities to significant compliance costs, legal liabilities, and operational disruptions, even absent formal classification as securities or commodities
NewRisks Related to Our Media Platform
Changes in tax law or adverse positions by tax authorities regarding crypto assets could result in increased tax burdens, reporting requirements, or other negative consequences
NewRisks Related to Our Media Platform
Environmental and social risks associated with crypto assets could lead to negative market perceptions of TAO and materially harm its value
NewRisks Related to Our Business and Financial Condition
subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practice, or cGMP, requirements and other regulations

Dropped

DroppedRisks Related to Our Business and Financial Condition
If we continue to execute our current development strategy, we will need additional financing to fund our operations in the future. If we are unable to obtain additional financing on acceptable terms, we will need to curtail or cease our development plans and operations
DroppedRisks Related to Our Business and Financial Condition
We have not generated any revenues since our inception and we do not expect to generate revenue for the foreseeable future. If we do not generate revenues and achieve and sustain profitability, we will likely need to curtail or cease our development plans and operations
Need for additional financing to fund operations and Phase 2 clinical trials.
DroppedRisks Related to Our Business and Financial Condition
Disruptions in federal government operations or extended government shutdowns may negatively impact our business
DroppedRisks Related to Our Business and Financial Condition
assessing their potential impacts on our business. In addition, sanctions on Russia and hostilities involving Israel could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds
DroppedRisks Relating to our Common Stock and the Securities Market
We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our Common Stock less attractive to investors

Reworded

73% rewrittenRisks Related to Our Business and Financial Condition
Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could materially and adversely affect us
No substantive changes were made to the internal control risk text.
69% rewrittenRisks Related to Our Business and Financial Condition
Even if regulatory approvals are obtained for our product candidates, we will be subject to ongoing government regulation. If we fail to comply with applicable current and future laws and government regulations, it could delay or prevent the promotion, marketing or sale of our products
Added a sentence fragment regarding manufacturers of drug products and their facilities.
61% rewrittenRisks Relating to our Common Stock and the Securities Market
As of December 31, 2025, we had an aggregate of 7,448,343 shares of Common Stock outstanding. Except for 163,540 shares, all of those shares are freely tradable without restriction or registration under the Securities Act of 1933, as amended (the “Securities Act”)
Updated share counts and financing details to reflect the October 2025 Series E Preferred Stock and warrant offering.
Was: As of December 31, 2024, we had an aggregate of 1,357,165 shares of Common Stock outstanding. Except for 7,681 shares, all of those shares are freely tradable without restriction or registration under the Securities Act of 1933, as amended (the “Securities Act”)
42% rewrittenRisks Related to Our Business and Financial Condition
Reforms in the healthcare industry and the uncertainty associated with pharmaceutical and laboratory test pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products
No substantive text changes were made regarding healthcare industry reforms.
33% rewrittenRisks Related to Our Business and Financial Condition
Our licensed patented technologies may infringe on other patents, which may expose us to costly litigation
No substantive text changes were made regarding licensed patented technology infringement risks.
25% rewrittenRisks Related to Our Business and Financial Condition
Consolidation in the pharmaceutical industry could materially affect our ability to operate as an independent entity
No substantive text changes were made regarding pharmaceutical industry consolidation.
21% rewrittenRisks Related to Our Business and Financial Condition
The commencement and completion of clinical trials can be delayed or prevented for a number of reasons
No substantive text changes were made regarding past Bryostatin-1 Phase 2 clinical trial results.

All 68 risk factors

Headings as the filing states them, in filing order.

Other

01There is no assurance that any crypto asset will maintain its value or that there will be meaningful levels of trading activities. In the event that the price of crypto assets or the demand for trading crypto assets decline, our business, operating results, and financial condition could be adversely affectedNew
02Certain of our directors, officers, employees and independent contractors may hold crypto assetsNew
03We are highly dependent on James Altucher and other key personnel, and our inability to retain or attract experienced individuals could materially harm our businessNew
04Our TAO holdings are likely to be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalentsNew
05Regulatory change classifying certain digital cryptocurrency assets as “securities” could lead to our being subject to extensive regulation, which could result in significant costs or force us to cease operationsNew
06We will likely need to pursue additional equity or debt financings to meet our previously announced goal of acquiring $100 million of TAONew
07Our historical financial statements do not reflect the potential variability in earnings that we may experience in the future relating to our proposed holdings of crypto assetsNew
08The emergence or growth of other crypto assets, including those with significant private or public sector backing, could have a negative impact on the price of TAO and adversely affect our businessNew

Risks Related to the Custodian and Prime Broker

09We face additional risks related to our reliance on BitGo Prime LLC (the “Prime Broker”) and BitGo Trust Company, Inc. (the “Custodian”), which are affiliated entities, for trading, custody, and settlement of TAONew
10Security threats to the Company’s account at the Custodian could result in the halting of the Company’s operations and a loss of the Company’s assets or damage to the reputation of the Company, each of which could materially and adversely affect the CompanyNew

Risks Related to Staking

11Staking activities involve significant risks, including the risks of borrower default, operational failures and the potential loss of TAO, which could materially and adversely affect our financial performance and the value of our crypto assetsNew
12Moreover, if any on-chain or implied protocol terms conflict with the Yuma Agreement, the agreement prevails. As the Bittensor protocol evolves, this “paramountcy” may cause frictions with network norms or expectations and may limit our ability to rely on protocol-level terms if they diverge from our contractNew
13Our reliance on the Custodian and its third-party validator for TAO staking activities creates concentration and related risksNew
14Our TAO staking relies on the Custodian and our Validators, who may utilize subnet automated market maker (“AMM”) pools, exposing us to additional liquidity, market, and operational risks beyond our direct controlNew
15If crypto assets held by us are determined to be securities under U.S. federal or state law, we would become subject to significant regulatory burdens, which may materially and adversely affect its business, operations, and financial conditionNew

Risks Related to Our Media Platform

16Our ownership and operation of The TAO Daily, an online news publication and data provider in the digital asset industry, presents a number of significant risks, including those arising from perceived or actual conflicts of interestNew
17Our strategy and focus on delivering high-quality, regulated, easy-to-use, and secure digital asset-related information through our media platform The TAO Daily may not maximize short-term or medium-term financial resultsNew
18Our success depends on our ability to effectively improve and scale our technical and data infrastructureNew
19Security incidents and other network and information systems disruptions could affect our ability to conduct our business effectively, cause us to incur significant costs, subject us to significant liability and/or damage our reputationNew
20We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure
21Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business
22Our business depends on continued and unimpeded access to the internet and cloud-based hosting services we utilizeNew
23Our advertising revenues are affected by numerous factors, including market dynamics, evolving digital advertising trends and the evolution of our strategyNew
24The open-source structure of crypto asset networks, including the Bittensor network on which the TAO crypto asset functions, exposes us to risks related to software development, security vulnerabilities, and potential disruptionsNew
25The irreversibility of crypto asset transactions exposes us to risks of theft, loss and human error, which could negatively impact our businessNew
26Decentralized AI networks, such as Bittensor, involve special risks related to unclear regulatory requirements, technical difficulties, limited transparency, intense competition, and complex intellectual property considerationsNew
27We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds, or to obligations applicable to investment advisers or other regulated entitiesNew
28Potential classification of our crypto asset activities including staking as money transmission could subject us to additional regulatory requirements, resulting in significant compliance costs or the cessation of certain operationsNew
29Regulatory scrutiny or shifting enforcement priorities could subject our crypto asset activities to significant compliance costs, legal liabilities, and operational disruptions, even absent formal classification as securities or commoditiesNew
30Changes in tax law or adverse positions by tax authorities regarding crypto assets could result in increased tax burdens, reporting requirements, or other negative consequencesNew
31Environmental and social risks associated with crypto assets could lead to negative market perceptions of TAO and materially harm its valueNew

Risks Related to Our Business and Financial Condition

32Our exploration and pursuit of strategic alternatives may not be successful
33Our ongoing viability as a company partially depends on our ability to successfully develop and commercialize our licensed technology
34If the CRE License were terminated, we may be required to cease product development operations
35We rely on independent third-party contract research organizations to perform clinical and non-clinical studies of our drug candidate and to perform other research and development services
36We have relied on the representations and materials provided by CRE, including scientific, peer-reviewed and non-peer reviewed publications, abstracts, slides, internal documents, verbal communications, patents and related patent filings, with respect to the results of its research related to our proposed products
37We have a limited operating history upon which investors can evaluate our future prospects
38If we do not obtain the necessary regulatory approvals in the United States and/or other countries, we will not be able to sell our drug candidate(s)
39The commencement and completion of clinical trials can be delayed or prevented for a number of reasons21% rewritten
40Even if regulatory approvals are obtained for our product candidates, we will be subject to ongoing government regulation. If we fail to comply with applicable current and future laws and government regulations, it could delay or prevent the promotion, marketing or sale of our products69% rewritten
41subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practice, or cGMP, requirements and other regulationsNew
42Data from our Bryostatin-1 Phase 2 clinical trial, from our confirmatory Phase 2 clinical trial and our expanded Phase 2 clinical trial may be subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company’s views of the data
43Our commercial success will depend, in part, on our ability, and the ability of our licensors, to obtain and maintain patent protection. Our licensors’ failure to obtain and maintain patent protection for our products may have a material adverse effect on our product development business
44Our licensed patented technologies may infringe on other patents, which may expose us to costly litigation33% rewritten
45We may not be able to protect our trade secrets and other unpatented proprietary technologies, which could give our competitors an advantage over us
46If we are unable to hire additional qualified personnel, our business prospects may suffer
47We may not be able to in-license or acquire new development-stage products or technologies
48We are partly dependent upon the NCI to supply bryostatin for our clinical trials
49We expect to rely on third parties to manufacture our proposed products and, as a result, we may not be able to control our product development or commercialization
50We may rely on third parties for marketing and sales and our revenue prospects may depend on their efforts
51If our products are not accepted by patients, the medical community or health insurance companies, our business prospects will suffer
52The branded prescription segment of the pharmaceutical industry in which we operate is competitive, and we are particularly subject to the risks of such competition
53Our business will expose us to potential product liability risks, which could result in significant product liability exposure
54A successful clinical trial liability claim against us could have a material adverse effect on our financial condition even with such insurance coverage
55A successful liability claim against us could have a material adverse effect on our financial condition
56Reforms in the healthcare industry and the uncertainty associated with pharmaceutical and laboratory test pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products42% rewritten
57Our business and operations would suffer in the event of computer system failures
58Consolidation in the pharmaceutical industry could materially affect our ability to operate as an independent entity25% rewritten
59Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could materially and adversely affect us73% rewritten
60Our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

Risks Relating to our Common Stock and the Securities Market

61The market price of our common stock has been volatile
62If we fail to meet the continued listing standards of Nasdaq, our common stock may be delisted, which may adversely affect the market price and liquidity of our common stock
63As of December 31, 2025, we had an aggregate of 7,448,343 shares of Common Stock outstanding. Except for 163,540 shares, all of those shares are freely tradable without restriction or registration under the Securities Act of 1933, as amended (the “Securities Act”)61% rewritten
64If securities or industry analysts do not publish research or publish misleading or unfavorable research about our business, our stock price and trading volume could decline
65We do not expect to pay any cash dividends for the foreseeable future
66Provisions in our certificate of incorporation, our bylaws or Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Common Stock
67You may experience dilution of your ownership interests because of the future issuance of additional shares of our Common Stock
68We may obtain additional capital through the issuance of preferred stock, which may limit your rights as a holder of our Common Stock

Other TAO Synergies 10-Ks

FY2024 10-K risk factors
43 risks
TAO Synergies faces high reliance on its lead drug Bryostatin-1, which failed its primary Phase 2 endpoint.
Filed Mar 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.